Ozempic Knock-Offs Contain Unsafe Substance, Novo Analysis Finds

Novo Nordisk A/S is suing two more compounded pharmacies over knock-off versions of Ozempic, including products found to contain a peptide that US regulators have deemed unsafe.

“We have seen concerning levels of unknown impurities as high as 33 percent and lower levels of strength than labeled in the compounded products, which could potentially put patient’s health at risk,” Jason Brett, executive director of medical affairs for Novo’s US affiliate, said in a statement released Thursday.

Novo has filed a total of 12 legal actions against medical spas, weight-loss clinics and compounding pharmacies selling dupes of its popular weight-loss and ...